Edge Therapeutics Priced, Nasdaq: EDGE

Developing a sustained-release therapy for limiting brain injury after aneurysms.

Industry: Health Care

Latest Trade: $10.07 0.00 (0.0%)

First Day Return: +17.6%

Return from IPO: -8.5%

Industry: Health Care

We are a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions. Our initial product candidates target rare, acute, life-threatening neurological conditions for which we believe the approved existing therapies are inadequate. We believe EG-1962, our lead product candidate, can fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. A single dose of EG-1962 is designed to deliver high concentrations of nimodipine, the current standard of care, directly to the brain with sustained drug exposure over 21 days. EG-1962 utilizes our proprietary, programmable, biodegradable polymer-based development platform, or our Precisa development platform, a novel delivery mechanism that enables targeted and sustained drug exposure while potentially avoiding the dose-limiting side effects associated with currently available formulations of nimodipine. On May 28, 2015, the Office of Orphan Product Development at the US Food and Drug Administration granted us orphan drug designation for EG-1962 for the treatment of patients with aSAH and on September 3, 2015 the European Union Committee on Orphan Medicinal Products issued a positive opinion for orphan drug designation of EG-1962 for treatment of aneurysmal subarachnoid hemorrhage.
more less
IPO News for Edge Therapeutics
more
IPO Data
IPO File Date 08/14/2015
Offer Price $11.00
Price Range $14.00 - $16.00
Offer Shares (mm) 7.3
Deal Size ($mm) $80
IPO Data
IPO Date 09/30/2015
Offer Price $11.00
Price Range $14.00 - $16.00
Offer Shares (mm) 7.3
Deal Size ($mm) $80
Underwriters
more
Company Data
Headquarters Berkeley Heights, NJ
Founded 2009
Employees 18
Website www.edgetherapeutics.com